Companion Diagnostics Driving New Model for Pharma-Dx Partnerships
US oncology patients are missing out on targeted therapies due to a combination of testing "quality gaps" and slow test diffusion
Subscribe to Clinical Diagnostics Insider to view
Start a Free Trial for immediate access to this article